Dr Richard Weaver
Richard is the founder and CEO of XenoGesis Limited. He set up the business in 2011, when he spotted a gap and opportunity in the market. Richard’s clear scientific and business direction, vision and entrepreneurial approach has seen XenoGesis consistently expand and grow to become the UK’s largest independent DMPK provider. The business works with over 150 companies and Universities across the globe and has provided experimental data, advice and PK predictions on seven compounds that are now in clinic. XenoGesis has grown from 3 to 26 employees in seven years, and in 2018, Richard led the move into state-of-the-art laboratories and offices at BioCity to provide the platform for future growth.
- The Importance of Human Dose And PK Prediction As Early As Possible
30 April 2019 11:50 am